Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26957837
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Middle+East+Afr+J+Ophthalmol
2016 ; 23
(1
): 38-43
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Clinical Trials in Branch Retinal Vein Occlusion
#MMPMID26957837
Panakanti TK
; Chhablani J
Middle East Afr J Ophthalmol
2016[Jan]; 23
(1
): 38-43
PMID26957837
show ga
Branch retinal vein occlusion (BRVO) is the second most common retinal vascular
disorder. The management of macular edema has changed considerably over time. The
laser is considered the gold standard treatment for over two decades. However,
visual recovery with laser is usually slow and incomplete. The advent of
intravitreal agents, specifically anti-vascular endothelial growth factors (VEGF)
have heralded a new era which promises rapid recovery of vision and quality of
vision. Randomized clinical trials have reported optimal results with anti-VEGF
agents (ranibizumab, bevacizumab, and aflibercept) compared to laser therapy or
steroids. However, nearly 50% of the patients require repeat intravitreal
anti-VEGF therapy up to 4 years after initiating therapy to sustain the visual
gains. The adverse events (systemic and ocular) of these agents are minimal.
Monotherapy with anti-VEGF agents have been found to provide better results than
any combination with laser. This review article summarizes evidence from
randomized controlled trials evaluating treatment options for the treatment of
macular edema secondary to BRVO with a special focus on anti-VEGF therapy.
free
free
free
